Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + vasopressin
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Local Injection
01
Overview
A combination of lidocaine and vasopressin used primarily for local anesthesia. Lidocaine acts as a local anesthetic by blocking sodium channels in nerve membranes, preventing the initiation and conduction of nerve impulses. Vasopressin causes vasoconstriction, which reduces local blood flow at the injection site. This reduction in blood flow decreases the rate at which lidocaine is removed from the area, promoting localization and retention of lidocaine in target tissues and extending the duration of anesthesia without significantly affecting overall circulatory dynamics.
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)AVPR1A (Arginine vasopressin receptor 1A)AVPR2 (Arginine vasopressin V2 receptor)AVPR1B (Vasopressin V1b Receptor)
Beyond the preview
Go deeper on lidocaine + vasopressin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + vasopressin.